Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

731 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study.
Miyake H, Matsumoto R, Fujimoto K, Mizokami A, Uemura H, Kamoto T, Kawakami S, Nakamura K, Maekawa S, Shibayama K, Watanabe A, Ito M, Tajima Y, Matsuyama H, Uemura H. Miyake H, et al. Among authors: matsuyama h. Eur Urol Oncol. 2024 Jun;7(3):625-632. doi: 10.1016/j.euo.2023.12.013. Epub 2024 Jan 30. Eur Urol Oncol. 2024. PMID: 38296736 Free article.
Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis.
Matsushita Y, Miyake M, Nishimura N, Nishimoto K, Fukuhara H, Kobayashi K, Oyama M, Inoue K, Matsuyama H, Fujimoto K, Miyake H. Matsushita Y, et al. Among authors: matsuyama h. Int J Clin Oncol. 2024 Feb;29(2):205-212. doi: 10.1007/s10147-023-02447-2. Epub 2023 Dec 19. Int J Clin Oncol. 2024. PMID: 38112832
Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.
Mori K, Hatakeyama S, Enokida H, Miyake H, Kikuchi E, Nishiyama H, Ichikawa T, Kamai T, Kaji Y, Kume H, Kondo T, Matsuyama H, Masumori N, Kawauchi A, Takenaka A, Uemura H, Eto M, Nonomura N, Fujii Y, Hinotsu S, Ohyama C. Mori K, et al. Among authors: matsuyama h. Int J Urol. 2024 Mar;31(3):194-207. doi: 10.1111/iju.15362. Epub 2023 Dec 19. Int J Urol. 2024. PMID: 38113344 Review.
GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
Yokomizo A, Shiota M, Morokuma F, Eto M, Matsuyama H, Matsumoto H, Kamoto T, Terada N, Kawahara K, Enokida H, Tatarano S, Fujimoto N, Higasijima K, Sakai H, Hakariya T, Igawa T, Suekane S, Kamba T, Sugiyama Y, Kishimoto J, Naito S. Yokomizo A, et al. Among authors: matsuyama h. Int J Urol. 2024 Apr;31(4):362-369. doi: 10.1111/iju.15371. Epub 2023 Dec 26. Int J Urol. 2024. PMID: 38148124 Clinical Trial.
The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study.
Shiota M, Tanegashima T, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, Kamba T, Fujimoto N, Yokomizo A, Naito S, Eto M. Shiota M, et al. Among authors: matsuyama h. Prostate Cancer Prostatic Dis. 2024 Feb 17. doi: 10.1038/s41391-024-00808-0. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38368501
Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines.
Miyake M, Kitamura H, Nishimura N, Miyamoto T, Nakahama T, Fujii T, Matsumoto H, Matsuyama H, Yonemori M, Enokida H, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Nishiyama H, Fujimoto K; Nishinihon Uro‐oncology Extensive Collaboration group and the Japanese Urological Oncology Group. Miyake M, et al. Among authors: matsuyama h. BJUI Compass. 2023 Nov 3;5(2):269-280. doi: 10.1002/bco2.305. eCollection 2024 Mar. BJUI Compass. 2023. PMID: 38371197 Free PMC article.
Photodynamic diagnosis-assisted transurethral resection of bladder tumor for high-risk non-muscle invasive bladder cancer improves intravesical recurrence-free survival (BRIGHT study).
Kawai T, Matsuyama H, Kobayashi K, Ikeda A, Miyake M, Nishimoto K, Matsushita Y, Nishiyama H, Fujimoto K, Oyama M, Miyake H, Azuma H, Inoue K, Mitsui T, Kawakita M, Oyama C, Mizokami A, Abe T, Kuroiwa H, Kume H. Kawai T, et al. Among authors: matsuyama h. Int J Urol. 2024 May 2. doi: 10.1111/iju.15483. Online ahead of print. Int J Urol. 2024. PMID: 38695571
Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer.
Miyake M, Nishimura N, Nakahama T, Nishimoto K, Oyama M, Matsushita Y, Miyake H, Fukuhara H, Inoue K, Kobayashi K, Matsuyama H, Fujii T, Hirao Y, Fujimoto K. Miyake M, et al. Among authors: matsuyama h. Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15474. Online ahead of print. Int J Urol. 2024. PMID: 38687165
731 results